ArticleArchives of medical science : AMS2024
Clinicopathologic characteristics, therapeutic modalities and survival outcomes of plasmablastic lymphoma: a real-world study.
Article in Archives of medical science : AMS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Survival benefits of chemotherapy, radiotherapy, and chemoradiotherapy in patients with unresectable intrahepatic cholangiocarcinoma: a population-based study.Archives of medical science : AMS · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Plasmablastic lymphoma (PBL), an extremely rare subtype of B-cell non-Hodgkin lymphoma (NHL), is characterized by aggressiveness, rapid progression and a bleak prognosis. Neither a standardized regimen nor a consensus for PBL treatment has been established. Material and methods: We retrospectively analyzed the clinicopathologic characteristics, therapeutic modalities and survival outcomes of 418 patients registered in the Surveillance, Epidemiology, and End Results (SEER) database from 2008 to 2016 and 21 (19 treated) patients in our institution. Kaplan-Meier survival curves and the log-rank test for overall survival (OS) and disease-specific survival (DSS) were performed to compare each variable. Variables with statistical significance in the univariate Cox regression were incorporated into the multivariate Cox model to determine the independent prognostic factors. Results: In the patient cohort from the SEER database, PBL has a striking male predilection. The median OS for all PBL patients was 17 months. The 1-year, 3-year and 5-year OS rates were 54.4%, 40.4% and 37.2% respectively. Patients who suffered from previous malignancy had a significant survival disadvantage compared to those without previous cancer. Patients with a higher Ann Arbor stage at diagnosis were at higher risk of death than those with a lower stage. Chemotherapy alone or chemotherapy combined with radiotherapy could significantly reduce the risk of death and extend the patients' survival, yielding a HR of 0.209 (95% CI: 0.152-0.288) and 0.187 (95% CI: 0.089-0.394), respectively. Radiation alone seemed useless. All patients from our institution were HIV-negative. The main therapeutic regimens were CHOP or CHOPE, DA-EPOCH, DHAP and ESHAP. A complete response (CR) was achieved in only 3 patients, while a partial response was achieved in 10 patients. The median OS was 7 months. Fourteen patients later died due to disease progression. Conclusions: Previous malignancy history, Ann Arbor stage and therapeutic modality were independent prognostic factors. Bortezomib combined with DA-EPOCH may serve as an effective regimen for PBL. The optimal therapeutic modality necessitates further exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.